|Videos|January 23, 2023
Critical Unmet Needs for Patients with MIBC and Ongoing Clinical Trials in the Neoadjuvant Setting
Author(s)Matthew Galsky, MD
Matthew Galsky, MD, highlights some remaining unmet needs for patients with MIBC, and currently ongoing clinical trials in the neoadjuvant MIBC treatment setting that excite him.
Advertisement
Episodes in this series
Advertisement
Related to this article
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5